Source:http://linkedlifedata.com/resource/pubmed/id/19843886
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
26
|
| pubmed:dateCreated |
2009-12-18
|
| pubmed:abstractText |
The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-alpha in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:ApperleyJane FJF,
pubmed-author:ChuahCharlesC,
pubmed-author:CortesJorgeJ,
pubmed-author:DufvaInge HIH,
pubmed-author:GilesFrancisF,
pubmed-author:GoldmanJohn MJM,
pubmed-author:HochhausAndreasA,
pubmed-author:KimDong-WookDW,
pubmed-author:MüllerMartin CMC,
pubmed-author:MartinelliGiovanniG,
pubmed-author:MauroMichael JMJ,
pubmed-author:NicoliniFranck EFE,
pubmed-author:PearsonJay DJD,
pubmed-author:PeterSenakaS,
pubmed-author:PreudhommeClaudeC,
pubmed-author:Sanz RodriguezCesarC,
pubmed-author:SoveriniSimonaS,
pubmed-author:YagasakiFumiharuF,
pubmed-author:ZhouWeiW
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
17
|
| pubmed:volume |
114
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5271-8
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19843886-Adolescent,
pubmed-meshheading:19843886-Adult,
pubmed-meshheading:19843886-Aged,
pubmed-meshheading:19843886-Aged, 80 and over,
pubmed-meshheading:19843886-Disease-Free Survival,
pubmed-meshheading:19843886-Drug Resistance, Neoplasm,
pubmed-meshheading:19843886-Female,
pubmed-meshheading:19843886-Genes, abl,
pubmed-meshheading:19843886-Humans,
pubmed-meshheading:19843886-Kaplan-Meier Estimate,
pubmed-meshheading:19843886-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19843886-Male,
pubmed-meshheading:19843886-Middle Aged,
pubmed-meshheading:19843886-Mutation,
pubmed-meshheading:19843886-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:19843886-Retrospective Studies,
pubmed-meshheading:19843886-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
|
| pubmed:affiliation |
Hematology Department, E Pavilion, Hôpital Edouard Herriot, 5 place d'Arsonval, 69437 Lyon, Cédex 03, France. franckemmanuel.nicolini@chu-lyon.fr
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|